Stocks Health care ANRO
NYSE · Health careAlto Neuroscience, Inc. (ANRO)
It posted a net loss of $84.2M. In fiscal 2025 capital spending exceeded operating cash flow by $51.8M. At June 30, 2026 it held $243.7M in cash against $16.2M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.
What Alto Neuroscience, Inc. does
Alto Neuroscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ANRO.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$63.2M | -$2.19 | -$51.8M |
| 2024 | n/a | -$61.4M | -$2.50 | -$49.5M |
| 2024 | n/a | -$36.3M | -$9.73 | -$33.9M |
Latest SEC filings
What Alto Neuroscience, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 27, 2026
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 14, 2026Passive stake changed SCHEDULE 13G/A
- August 12, 2026Quarterly report 10-Q · period to June 30, 2026
- August 12, 2026
- July 27, 2026Passive stake (5% or more) SCHEDULE 13G
- July 20, 2026Passive stake (5% or more) SCHEDULE 13G
- July 14, 2026
- July 14, 2026
Questions about ANRO
What does Alto Neuroscience, Inc. do?
Alto Neuroscience, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker ANRO.
Is Alto Neuroscience, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $84.2M.
When did Alto Neuroscience, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the executive or director change from August 27, 2026.
Similar companies
Follow ANRO
Get an email when Alto Neuroscience, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow ANRO: get an email when it filesWhere the numbers come from
Financial figures are the values Alto Neuroscience, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.